When can a patient with controlled hypertension on 30mg lisinopril and prediabetes with HbA1c of 5.8% discontinue statin therapy and consider metformin initiation?

Statin Discontinuation and Metformin Initiation in Controlled Hypertension with Prediabetes

Statin Discontinuation

Statins should generally not be discontinued in this patient, as the cardiovascular benefits outweigh risks even in the presence of prediabetes, and discontinuation is only appropriate when functional decline, multimorbidity, frailty, or reduced life expectancy limits potential benefits. 1

When Statin Discontinuation May Be Considered

• In adults 75 years or older, it may be reasonable to stop statin therapy when functional decline (physical or cognitive), multimorbidity, frailty, or reduced life-expectancy limits the potential benefits. 1

• Statin-associated side effects are the primary reason for discontinuation, not simply patient preference or the presence of prediabetes. 1

• Severe statin-associated side effects such as rhabdomyolysis (risk <0.1%) or statin-associated autoimmune myopathy require statin cessation, though reversible causes should be sought first. 1, 2

Why Statins Should Be Continued Despite Prediabetes

• The cardiovascular benefits of statin therapy outweigh the risk of new-onset diabetes, and the possibility of incident diabetes should not be a contraindication to statin therapy or indication for discontinuation. 1

• Statins modestly increase the risk of incident diabetes in individuals with predisposing risk factors and metabolic syndrome components, but this represents a small number of susceptible individuals crossing the threshold rather than statins directly causing diabetes. 1

• For every case of diabetes that might develop with statin therapy, an estimated 5 to 9 ASCVD events may be prevented. 1

• In patients with diabetes aged 40-75 years, moderate-intensity statin therapy is indicated regardless of estimated 10-year ASCVD risk, and high-intensity therapy is recommended for those with additional ASCVD risk factors. 1

Management Strategy if Patient Desires Discontinuation

• Engage in shared decision-making that emphasizes the net clinical benefit, discussing that the small diabetes risk is outweighed by cardiovascular protection. 1

• Intensify lifestyle modifications including regular moderate physical activity, maintaining a healthy dietary pattern, and sustaining modest weight loss according to Diabetes Prevention Program principles. 1

• If statin-associated symptoms are the concern, use the "reassess, rediscuss, and rechallenge" strategy with a reduced dose, alternative agent, or alternative dosing regimen while monitoring for recurrent symptoms. 1

---

Metformin Initiation for Prediabetes (A1C 5.8%)

Metformin should be considered now for this patient with prediabetes (A1C 5.8%) who has additional ASCVD risk factors (hypertension requiring treatment), as it is a reasonable pharmacologic option that is well-tolerated, low-cost, and not associated with hypoglycemia. 3

Indications for Metformin in Prediabetes

• Metformin is indicated for patients with prediabetes (A1C 5.7-6.4%) who have additional cardiovascular risk factors such as hypertension, dyslipidemia, or obesity. 3

• The American Diabetes Association prevention approach encourages lifestyle modifications as first-line, but metformin is a reasonable addition when risk factors are present. 1

• For adults with type 2 diabetes requiring glucose-lowering therapy, metformin should be used as first-line therapy along with lifestyle modifications at the time of diagnosis. 1

Monitoring After Metformin Initiation

• Monitor A1C every 3 months to assess response to therapy. 3

• Consider periodic testing of vitamin B12 levels during long-term metformin therapy. 3

• If A1C normalizes (<5.7%), consider de-intensifying therapy and transitioning to lifestyle management focusing on diet, exercise, and weight management. 4, 3

• If A1C progresses to diabetes range (≥6.5%), reassess treatment strategy and consider additional therapies. 3

Common Pitfalls to Avoid

• Do not wait until A1C reaches diabetes threshold (≥6.5%) to initiate metformin in patients with prediabetes and additional cardiovascular risk factors, as early intervention may prevent progression. 3

• Do not discontinue statins due to concerns about diabetes risk when metformin can be added to manage glucose levels while maintaining cardiovascular protection. 1

• Do not neglect lifestyle modifications as the foundation of therapy—metformin is an adjunct, not a replacement for diet, exercise, and weight management. 1